| abstract |
REFERS TO COMPOUNDS DERIVED FROM TRIAZOLOPYRAZINE OF FORMULA (I) WHERE R1 AND R2 ARE EACH H, F, ALKYL (C1-C6), CYCLOALKYL (C3-C8), ALKENYL (C2-C6), AMONG OTHERS; R3 IS A COMPOUND OF FORMULA (i) WHERE R5, R6, R7, R8 AND R9 ARE EACH H, CN, NO2, ARYL (C6-C10), ALKINYL (C2-C6), AMONG OTHERS; R4 IS H, F, ALKYL (C1-C6) OR ARYL (C6-C12). PREFERRED COMPOUNDS ARE: 6 - ((6- (1-METHYL-1H-PYRAZOLE-4-IL) -1H- [1,2,3] TRIAZOLO [4,5-b] PYRAZIN-1-IL) METHYL) QUINOLINE , N- (PIPERIDIN-4-IL) -4- (3- (QUINOLIN-6-ILMETHYL) -3H- [1,2,3] TRIAZOLO [4,5-b] PIRAZIN-5-IL) BENZAMIDE, N - (2-AMINOETHYL) -4- (3- (QUINOLIN-6-ILMETHYL) -3H- [1,2,3] TRIAZOLO [4,5-b] PIRAZIN-5-IL) BENZAMIDE, AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION. THESE COMPOUNDS ARE MODULATORS OF THE RECEPTOR OF THE HEPATOCYTE GROWTH FACTOR (c-MET OR HGFR) BEING USEFUL IN THE TREATMENT OF BREAST CANCER, GLIOMA, MELANOMA, LEUKEMIA |